BioXcel Therapeutics Receives FDA Approval For Igalmi
<p>Yesterday, FDA announced its approval of <a href='https://financialmodelingprep.com/financial-summary/BTAI'>BioXcel Therapeutics, Inc’s (NASDAQ:BTAI)</a> Igalmi (BXCL501). Analysts at Berenberg Bank think continued outperformance in 2022 is likely, particularly as 2022 should be the first year BioXcel transforms from a clinical to a commercial-stage company since its IPO in 2018. </p>
<p>The analysts’ estimates of Igalmi sales are unchanged and continue to call for Igalmi to reach blockbuster status in the U.S. in the 2030- 2031 time frame, driven in part by the label expansion to include additional indications.</p>
<p>Overall, the analysts think the company’s shares are compelling ahead of several potential positive events over the next year, including pipeline study readouts.</p>

NASDAQ:BTAI